# Evaluating the Impact of Financial Navigation on Financial Catastrophe and Distress for Cancer Care: A Randomized Control Trial- COST-FIN

**Authors:** Amir H. Sohail, Oluwasegun Afolaranmi, Funmilola Olanike Wuraola, Matthew Caputo, George Guiterrez, Adewale Oyewole, Dorcas O. Ebekue, Zainab Oyindamola Adegbite, Clement Awe, Titilope Ogunniyi, Akinlusi Opeyemi, Chinyere Nwankwo, Frances Uwechue, Dan Sherman, Clara N. Lambert, Joseph Adedayo, Kristina Diaz, Elizabeth Nicole Christian, Fatimah Abdulkareem, Olufemi Akin-Adigun, Adewunmi Akingbola, Sophia Okeke, Gregory Knapp, Anna Dare, Toluwanimi Aduloju, Moyinoluwa Akinwumi, Ciaran Navin Kohli-Lynch, Ruohui Chen, Chukwumere Nwogu, Lisa R Hirschhorn, Andrei Adin-Cristian, Chinenye Iwuji, Oge Ilegbune, Mutiu Jimoh, Bindiya Chugani, Olise Oputa, Shilpa Murthy, Dustin French, Ron Ackermann, Robert Murphy, Anthony Seddoh, Peter Kingham, Olusegun Isaac Alatise, Juliet S Lumati

PMC · DOI: 10.21203/rs.3.rs-7686399/v1 · Research Square · 2026-01-21

## TL;DR

This study evaluates a financial navigation program in Nigeria to reduce the financial burden of cancer care and its impact on patients.

## Contribution

The study is the first randomized controlled trial of a Financial Navigation Program in a resource-constrained setting like Nigeria.

## Key findings

- The trial will assess the impact of financial navigation on reducing financial catastrophe and distress in cancer patients.
- It will explore cost-related non-adherence and the cost-effectiveness of the program.
- Findings could influence policy reform and scalability of financial navigation in low-resource settings.

## Abstract

As with most Sub-Saharan African countries, Nigeria has a rising incidence of cancer, with disproportionate mortality rates. The financial burden of cancer care often results in catastrophic healthcare spending, leading to treatment refusal, disruption, and discontinuation. This is particularly significant in Nigeria, where nearly all patients are uninsured, and out-of-pocket costs often exceed households’ ability to pay. Financial Navigation Programs (FNPs) have been shown to mitigate treatment-related financial toxicity in cancer care and reduce treatment abandonment, but there is a paucity of high-quality data on this intervention in resource-constrained settings. Here, we present a randomized controlled trial to evaluate the impact of a novel FNP in Nigeria.

We designed the COST-FIN trial, a multi-site pragmatic single-blinded randomized controlled trial of newly diagnosed (<6 weeks from diagnosis) adults (≥18 years) with breast, colorectal, or prostate cancer at two tertiary cancer centers in Nigeria. Participants (n=200) will be randomized (1:1) to either the intervention (FNP) or the control arm and followed for 12 months. Data on key individual, treatment, and financial parameters will be collected via structured interviews and chart abstraction at baseline, 3, 6, and 12-month follow-up. In addition, participants randomized to the FNP will receive a tailored financial literacy assessment, financial planning support, and enhanced access to resources by trained financial navigators. Primary and secondary outcomes are Financial Catastrophe (FC) and Financial Distress (FD), respectively. Exploratory outcomes will include cost-related non-adherence and cost-effectiveness of the program. An interim analysis will be conducted when 50% of the estimated accruals reach 6 months of follow-up, with crossover if compelling evidence of benefit is demonstrated at that time point. All participants will be followed for 12 months from recruitment.

This first-of-its-kind study will provide evidence on the role of FNP in potentially eliminating financial barriers to cancer care in Nigeria. Given the country’s renewed interest in cancer control through the passage of the National Cancer Control Plan, findings from this study have the potential to influence policy reform and set the stage for further studies to evaluate the scalability and implementation of similar interventions in resource-limited settings.

ClinicalTrials.gov
NCT06630962. Oct 8, 2024 (https://clinicaltrials.gov/study/NCT06630962)

## Linked entities

- **Diseases:** cancer (MONDO:0004992), breast cancer (MONDO:0004989), colorectal cancer (MONDO:0005575), prostate cancer (MONDO:0005159)

## Full-text entities

- **Diseases:** Cancer (MESH:D009369), toxicity (MESH:D064420), breast, colorectal, or prostate cancer (MESH:D001943)
- **Chemicals:** FNP (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12869642/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12869642/full.md

## References

71 references — full list in the complete paper: https://tomesphere.com/paper/PMC12869642/full.md

---
Source: https://tomesphere.com/paper/PMC12869642